

# Contents

Preface, xii

## 1 Introduction, 1

Classification of cutaneous lymphomas, 1

Examination of patients, 2

Staging investigations, 2

Surgical techniques, 2

Histopathology, immunophenotype, and molecular genetics, 4

Other methods used in the study of cutaneous lymphoid infiltrates, 11

Lymphoma microenvironment and lymphoma-associated microorganisms, 11

Pseudomalignancy, premalignancy, and early malignancy, 12

## Section 1: Cutaneous NK/T-cell lymphomas and lymphoproliferative disorders

### 2 The “parapsoriasis”, 17

### 3 Mycosis fungoides, 26

Onset of mycosis fungoides or exacerbation of undiagnosed disease under treatment with immunomodulatory agents, 28

Clinical features, 29

Extracutaneous involvement, 34

Association with other diseases, 37

Histopathology, immunophenotype, and molecular genetics, 39

Histopathologic differential diagnosis from inflammatory conditions, 61

Clinical and histopathologic variants, 62

Mycosis fungoides in children and adolescents, 99

Treatment, 100

Prognosis, 111

### 4 Sézary syndrome, 135

Onset/progression under systemic therapies for benign inflammatory dermatoses, 137

Clinical features, 137

Histopathology, immunophenotype, and molecular genetics, 145

Treatment, 149

Prognosis, 151

### 5 Primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders, 158

Lymphomatoid Papulosis, 159

Cutaneous Anaplastic Large Cell Lymphoma, 180

“Borderline” Cases, 198

Intralymphatic CD30<sup>+</sup> Large T-Cell Lymphoma, 199

Implant-associated anaplastic large cell lymphoma, 202

### 6 Subcutaneous panniculitis-like T-cell lymphoma, 211

Clinical features, 212

Histopathology, immunophenotype, and molecular genetics, 214

Differential diagnosis with other cutaneous NK/T-cell lymphomas with prominent involvement of the subcutaneous tissue, 218

Differential diagnosis with lupus panniculitis, 218

Treatment, 219

Prognosis, 223

- 7** Primary cutaneous aggressive epidermotropic CD8<sup>+</sup> cytotoxic T-Cell lymphoma, 227
    - Clinical features, 227
    - Histopathology, immunophenotype, and molecular genetics, 227
    - Treatment, 233
    - Prognosis, 236
  - 8** Primary cutaneous  $\gamma/\delta$  T-cell lymphoma, 240
    - Clinical features, 242
    - Histopathology, immunophenotype, and molecular genetics, 243
    - Prognosis, 248
  - 9** Cutaneous extranodal NK/T-cell lymphoma, nasal type, 254
    - Clinical features, 254
    - Histopathology, immunophenotype, and molecular genetics, 256
    - Treatment, 262
    - Prognosis, 263
  - 10** Cutaneous peripheral T-cell lymphoma, not otherwise specified (NOS), 266
    - Clinical features, 267
    - Histopathology, immunophenotype, and molecular genetics, 268
    - Treatment, 272
    - Prognosis, 272
  - 11** Cutaneous CD4<sup>+</sup> small–medium T-cell lymphoproliferative disorder, 278
    - Clinical features, 280
    - Histopathology, immunophenotype, and molecular genetics, 281
    - Treatment, 284
    - Prognosis, 284
    - Final considerations, 284
  - 12** Primary cutaneous acral CD8<sup>+</sup> T-cell lymphoproliferative disorder, 287
    - Clinical features, 287
    - Histopathology, immunophenotype, and molecular genetics, 287
    - Treatment, 288
    - Prognosis, 288
  - 13** Cutaneous adult T-cell leukemia/lymphoma, 291
    - Clinical features, 291
    - Histopathology, 291
    - Immunophenotype, 291
    - Molecular genetics, 293
    - Treatment, 293
    - Prognosis, 293
  - 14** Specific cutaneous manifestations of nodal T-follicular helper cell lymphoma, angioimmunoblastic type, and of other nodal T-follicular helper cell lymphomas, 296
    - Clinical features, 296
    - Histopathology, 296
    - Immunophenotype, 299
    - Molecular genetics, 299
    - Treatment, 299
    - Prognosis, 299
  - 15** Cutaneous manifestations in Epstein–Barr virus-positive T-cell and NK-cell lymphoid proliferations and lymphomas of childhood, 304
    - Severe mosquito bite allergy, 304
    - Hydroa-vacciniforme lymphoproliferative disorders, 305
      - Classic hydroa vacciniforme, 306
      - Systemic hydroa vacciniforme lymphoproliferative disorder, 309
- Section 2: Cutaneous B-cell lymphomas and lymphoproliferative disorders**
- 16** Cutaneous follicle center lymphoma, 317
    - Clinical features, 317
    - Histopathology, immunophenotype, and molecular genetics, 321
    - Differential diagnosis of cutaneous follicle center lymphoma, diffuse type, from cutaneous diffuse large B-cell lymphoma, leg type, 336
    - Treatment, 336
    - Prognosis, 337

- 17** Primary cutaneous marginal zone lymphoproliferative disorder (primary cutaneous marginal zone lymphoma) and variants, 341
- Cutaneous marginal zone lymphoproliferative disorder, conventional variant, 343
  - Clinical features, 344
  - Histopathology, immunophenotype, and molecular genetics, 345
  - Treatment, 354
  - Prognosis, 355
  - Cutaneous marginal zone lymphoproliferative disorder, lymphoplasmacytic variant, 356
  - Clinical features, 356
  - Histopathology, immunophenotype, and molecular genetics, 356
  - Treatment, 358
  - Prognosis, 358
  - Cutaneous marginal zone lymphoproliferative disorder, plasmacytic variant, 359
  - Clinical features, 359
  - Histopathology, immunophenotype, and molecular genetics, 359
  - Treatment and prognosis, 359
  - Cutaneous marginal zone lymphoproliferative disorder, blastoid variant, 361
  - Clinical features, 361
  - Histopathology, immunophenotype, and molecular genetics, 361
  - Treatment and prognosis, 362
  - Cutaneous amyloidoma, 362
  - Clinical features, 364
  - Histopathology, immunophenotype, and molecular genetics, 364
  - Treatment and prognosis, 364
- 18** Cutaneous diffuse large B-cell lymphoma, leg type, 370
- Clinical features, 371
  - Histopathology, immunophenotype, and molecular genetics, 372
  - Treatment, 380
  - Prognosis, 380
- Primary cutaneous diffuse large B-cell lymphoma, NOS, 381
- 19** Intravascular large cell lymphomas, 387
- Intravascular large B-cell lymphoma, 388
  - Intravascular large NK/T-cell lymphoma, 394
- 20** Other cutaneous B-cell lymphomas, 400
- Cutaneous manifestations of Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma, 400
  - Cutaneous manifestations of mantle cell lymphoma, 403
  - Cutaneous manifestations of extracavitary primary effusion lymphoma, 408
  - Cutaneous manifestations of multiple myeloma, 411
  - Cutaneous manifestations of Burkitt lymphoma, 414
  - Cutaneous lymphomatoid granulomatosis, 416
  - Cutaneous plasmablastic lymphoma, 419
  - Cutaneous T-cell/histiocyte-rich large B-cell lymphoma, 420
  - Cutaneous manifestations of Waldenström macroglobulinemia, 424
- Section 3: Cutaneous lymphomas and lymphoproliferative disorders in the setting of immune deficiency / dysregulation**
- 21** Cutaneous lymphoproliferative disorders and lymphomas in the setting of immune deficiency/dysregulation, 433
- Posttransplant immunodeficiency/dysregulation, 439
  - Human immunodeficiency virus (HIV)-related immune deficiency/dysregulation, 439
  - Cutaneous plasmacytic hyperplasia associated with immune deficiency/dysregulation, 441
  - Cutaneous polymorphic B-cell lymphoproliferative disorder associated with immune deficiency/dysregulation, 443
  - Epstein–Barr virus (EBV)-associated mucocutaneous ulcers, 446
  - Cutaneous manifestations of multicentric Castleman disease, 448

## Section 4: Specific cutaneous manifestations of leukemias and of precursor hematologic neoplasms

- 22** Cutaneous manifestations of B-cell chronic lymphocytic leukemia, 455
  - Clinical features, 455
  - Histopathology, immunophenotype, and molecular genetics, 456
  - Treatment and prognosis, 461
  - Progression to diffuse large B-cell lymphoma (Richter syndrome), 464
- 23** Cutaneous manifestations of myelogenous leukemia, 471
  - Acute myeloid leukemia, 472
  - Chronic myelogenous leukemia, 484
  - Myelodysplastic syndromes (myelodysplastic neoplasms), 489
  - Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasms, 492
- 24** Blastic plasmacytoid dendritic cell neoplasm, 495
  - Clinical features, 495
  - Histopathology, immunophenotype, and molecular genetics, 497
  - Treatment, 502
  - Prognosis, 503
- 25** Cutaneous manifestations of other leukemias, 507
  - T-cell prolymphocytic leukemia, 507
  - Aggressive natural killer cell leukemia, 509
  - Specific skin manifestations of other types of leukemia, 510
- 26** Cutaneous lymphoblastic lymphomas, 513
  - Cutaneous B-Lymphoblastic Lymphoma, 513
  - Clinical features, 514
  - Histopathology, immunophenotype, and molecular genetics, 514
  - Differential diagnosis, 516
  - Treatment and prognosis, 517
  - Cutaneous T-Lymphoblastic Lymphoma, 518
  - Clinical features, 518

Histopathology, immunophenotype, and molecular genetics, 519

Treatment and prognosis, 519

## Section 5: Cutaneous manifestations of other lymphomas and non-neoplastic cutaneous signs of systemic lymphomas

- 27** Cutaneous manifestations of Hodgkin lymphoma, 527
  - Clinical features, 528
  - Histopathology, immunophenotype, and molecular genetics, 528
  - Treatment and prognosis, 530
  - Primary cutaneous Hodgkin lymphoma, 530
- 28** Cutaneous composite lymphomas, 533
  - Clinical features, 534
  - Histopathology, immunophenotype, and molecular genetics, 534
  - Treatment and prognosis, 538
- 29** Non-neoplastic cutaneous signs of systemic lymphomas, 541

## Section 6: Cutaneous lymphomas and lymphoproliferative disorders in children and adolescents

- 30** Cutaneous lymphomas and lymphoproliferative disorders in children and adolescents, 599
  - Mycosis fungoides, 599

## Section 7: Pseudolymphomas of the skin

- 31** Pseudolymphomas of the skin, 577
  - Chronic actinic dermatitis (actinic reticuloid), 578
  - Lymphomatoid contact dermatitis, 580
  - Pseudolymphomatous atopic dermatitis and other eczematous dermatoses, 582
  - Non-neoplastic erythroderma in adult patients, 592
  - Solitary idiopathic T/B-cell pseudolymphoma, 598
  - Lichenoid/lymphomatoid keratosis, 600
  - Pityriasis lichenoides, 601

- Lichen aureus/lichenoid pigmented purpuric dermatitis, 605
- Lichen sclerosus, 606
- Vitiligo (inflammatory stage), 609
- Annular lichenoid dermatitis of youth, 609
- Pseudolymphomatous cutaneous infiltrates in human immunodeficiency virus (HIV)-infected patients and in other immune deficiencies, 609
- CD30<sup>+</sup> T-cell pseudolymphomas, 614
- Persistent nodular arthropod bite reactions and nodular scabies, 616
- Pseudolymphomas in herpes simplex and herpes zoster infections, 620
- Pseudolymphomas associated with lupus erythematosus, 621
- Lymphomatoid drug reactions, 630
- Lymphocytoma cutis, 633
- Pseudolymphomas associated with infections by *Borrelia* species, 635
- Pseudolymphomas at sites of vaccination, 642
- Localized scleroderma/morphea, 647
- Cutaneous IgG4-related disease, 649
- Pseudolymphomas in syphilis, 649
- Cutaneous plasma cell granuloma, 654
- Cutaneous and systemic plasmacytosis, 655
- Angiomatoid pseudolymphoma (T-cell-rich angiomatoid polypoid pseudolymphoma / Acral pseudolymphomatous angiokeratoma in children / Pre-tibial lymphoplasmacytic plaque in children), 655
- Cutaneous extramedullary hematopoiesis, 658
- Histiocytoid cells in Sweet syndrome and other conditions, 659
- Intralymphatic histiocytosis, 661
- Benign intralymphatic proliferation of T-cell lymphoid blasts, 662
- Other “accidental” pseudolymphomas, 667
- 32** Nonlymphoid malignant neoplasms of the skin mimicking histopathologically cutaneous lymphomas (“malignant pseudolymphomas”), 677
- Section 8: The cutaneous “atypical lymphoid proliferation”**
- 33** The cutaneous “atypical lymphoid proliferation”, 687
- Index, 690